Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Myeloid 1Sarcoma 1Rhabdomyosarcoma 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Leukemia, Myeloid, Acute 1Ganglioneuroblastoma 1Blast Crisis 1

Interventions

X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4Vincristine 3Specimen Handling 3Irinotecan 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2ensartinib 2Temozolomide 2Radiotherapy 2temsirolimus 1tazemetostat 1talazoparib 1palbociclib 1olaparib 1liposomal doxorubicin 1irinotecan sucrosofate 1fludarabine phosphate 1fludarabine 1erdafitinib 1cabozantinib 1atezolizumab 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Dexrazoxane × 30 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡